Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Filter bei nächster Suche beibehalten
journalStr:"WHO International Clinical Trials Registry Platform"
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?lookfor=%22Macrophage+activation+syndrome%22&type=Subject&filter%5B%5D=journalStr%3A%22WHO+International+Clinical+Trials+Registry+Platform%22
/vufind/Search/Results?lookfor=%22Macrophage+activation+syndrome%22&type=Subject&filter%5B%5D=journalStr%3A%22WHO+International+Clinical+Trials+Registry+Platform%22
Search /vufind/Search2/Results?lookfor=%22Macrophage+activation+syndrome%22&type=Subject&filter%5B%5D=journalStr%3A%22WHO+International+Clinical+Trials+Registry+Platform%22
PubPharm (38)
1
Clinical Multicenter Study of Tocilizumab in the Treatment of sJIA-MAS : Clinical multicenter study of interleukin-6 inhibitor in the treatment of systemic juvenile idiopathic arthritis complicated with macrophage activation syndrome
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
2
Clinical Multicenter Study of Tocilizumab in the Treatment of sJIA-MAS : Clinical multicenter study of interleukin-6 inhibitor in the treatment of systemic juvenile idiopathic arthritis complicated with macrophage activation syndrome
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
3
A study to see if a drug called gemtuzumab ozogamicin is a useful treatment for patients with immune disorders called haemophagocytic lymphohistiocytosis (HLH) or macrophage activation syndrome (MAS), or for patients with cancer : A phase II trial to assess the activity of Gemtuzumab Ozogamicin Therapy in Haemophagocytic lymphohistiocytosis (HLH) or Macrophage activation syndrome (MAS) or relapsed/refractory solid tumours (GOTHAM)
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
4
A study to see if a drug called gemtuzumab ozogamicin is a useful treatment for patients with immune disorders called haemophagocytic lymphohistiocytosis (HLH) or macrophage activation syndrome (MAS), or for patients with cancer : A phase II trial to assess the activity of Gemtuzumab Ozogamicin Therapy in Haemophagocytic lymphohistiocytosis (HLH) or Macrophage activation syndrome (MAS) or relapsed/refractory solid tumours (GOTHAM)
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
5
Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE : A Two-cohort, Open-label, Single-arm, Multicenter Study to Evaluate Efficacy, Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of Emapalumab in Children and Adults with Macrophage Activation Syndrome (MAS) in Still's Disease (Including Systemic Juvenile Idiopathic Arthritis and Adult Onset Still's Disease) or with MAS in Systemic Lupus Erythematosus - EMERALD
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
6
Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE : A Two-cohort, Open-label, Single-arm, Multicenter Study to Evaluate Efficacy, Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of Emapalumab in Children and Adults with Macrophage Activation Syndrome (MAS) in Still's Disease (Including Systemic Juvenile Idiopathic Arthritis and Adult Onset Still's Disease) or with MAS in Systemic Lupus Erythematosus - EMERALD
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
7
A study to evaluate efficacy, safety and tolerability, pharmacokinetics and pharmacodynamics of emapalumab in children and adults with macrophage activation syndrome (MAS) : A Two-cohort, Open-label, Single arm, Multicenter Study to Evaluate Efficacy, Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of Emapalumab in Children and Adults with Macrophage Activation Syndrome (MAS) in Still’s disease (Including Systemic Juvenile Idiopathic Arthritis and Adult onset Still’s disease) or with MAS in Systemic Lupus Erythematous - NI-0501-14
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
8
A study to evaluate efficacy, safety and tolerability, pharmacokinetics and pharmacodynamics of emapalumab in children and adults with macrophage activation syndrome (MAS) : A Two-cohort, Open-label, Single arm, Multicenter Study to Evaluate Efficacy, Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of Emapalumab in Children and Adults with Macrophage Activation Syndrome (MAS) in Still’s disease (Including Systemic Juvenile Idiopathic Arthritis and Adult onset Still’s disease) or with MAS in Systemic Lupus Erythematous - NI-0501-14
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
9
A study to evaluate efficacy, safety and tolerability, pharmacokinetics and pharmacodynamics, of emapalumab in children and adults with macrophage activation syndrome (MAS) : A two-cohort, open-label, single arm, multicenter study to evaluate efficacy, safety and tolerability, pharmacokinetics and pharmacodynamics, of emapalumab in children and adults with macrophage activation syndrome (MAS) in Still’s disease (including systemic juvenile idiopathic arthritis and Adult onset Still’s disease) or with MAS in Systemic lupus erythematous - NI-0501-14
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
10
A study to evaluate efficacy, safety and tolerability, pharmacokinetics and pharmacodynamics, of emapalumab in children and adults with macrophage activation syndrome (MAS) : A two-cohort, open-label, single arm, multicenter study to evaluate efficacy, safety and tolerability, pharmacokinetics and pharmacodynamics, of emapalumab in children and adults with macrophage activation syndrome (MAS) in Still’s disease (including systemic juvenile idiopathic arthritis and Adult onset Still’s disease) or with MAS in Systemic lupus erythematous - NI-0501-14
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
1
2
3
4
Nächster »
[4]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Clinical Studies
Patente
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Ihre gewählten Filter
Filter bei nächster Suche beibehalten
Filter aufheben
Zeitschrift: WHO International Clinical Trials Registry Platform
Medienart
38
Aufsätze
38
E-Artikel
38
E-Ressourcen
Zeitschriftentitel
WHO International Clinical Trials Registry Plat...
Thema
38
610
36
Study Type: Interventional
30
Phase: Phase 2
12
Medical Condition: Macrophage activation syndro...
8
Recruitment Status: Authorised-recruitment may ...
8
Recruitment Status: Not yet recruiting
8
Recruitment Status: Recruiting
4
Medical Condition: Macrophage activation syndro...
2
Medical Condition: Haemophagocytic lymphohistio...
2
Medical Condition: Haemophagocytic lymphohistio...
2
Medical Condition: Juvenile idiopathic arthriti...
2
Medical Condition: Macrophage Activation Syndro...
2
Medical Condition: Macrophage activation syndrome
2
Medical Condition: Macrophage activation syndro...
2
Medical Condition: Macrophage activation syndro...
2
Medical Condition: Macrophage activation syndro...
2
Medical Condition: Macrophage activation syndro...
2
Medical Condition: Macrophage activation syndro...
2
Medical Condition: severe illness patients with...
2
Phase: Phase 2/Phase 3
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
36
2020-
2
2010-2019
Erscheinungsjahr(e)
Von:
Bis:
Sprache
38
Englisch
Haven't found what you're looking for?
Wird geladen...